Recent insights in striated muscle laminopathies.
Journal
Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162
Informations de publication
Date de publication:
12 Jul 2024
12 Jul 2024
Historique:
medline:
11
7
2024
pubmed:
11
7
2024
entrez:
11
7
2024
Statut:
aheadofprint
Résumé
To highlight recent insights in different aspects of striated muscle laminopathies (SMLs) related to LMNA mutations. Clinical and genetic studies allow better patient management and diagnosis, with confirmation of ventricular tachyarrhythmias (VTA) risk prediction score to help with ICD implantation and development of models to help with classification of LMNA variants of uncertain significance. From a pathophysiology perspective, characterization of lamin interactomes in different contexts revealed new lamin A/C partners. Expression or function modulation of these partners evidenced them as potential therapeutic targets. After a positive phase 2, the first phase 3 clinical trial, testing a p38 inhibitor targeting the life-threatening cardiac disease of SML, has been recently stopped, thus highlighting the need for new therapeutic approaches together with new animal and cell models. Since the first LMNA mutation report in 1999, lamin A/C structure and functions have been actively explored to understand the SML pathophysiology. The latest discoveries of partners and altered pathways, highlight the importance of lamin A/C at the nuclear periphery and in the nucleoplasm. Modulation of altered pathways allowed some benefits, especially for cardiac involvement. However, additional studies are still needed to fully assess treatment efficacy and safety.
Identifiants
pubmed: 38989655
doi: 10.1097/WCO.0000000000001297
pii: 00019052-990000000-00179
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Kochin V, Shimi T, Torvaldson E, et al. Interphase phosphorylation of lamin A. J Cell Sci 2014; 127:2683–2696.
Paulsen J, Sekelja M, Oldenburg AR, et al. Chrom3D: three-dimensional genome modeling from Hi-C and nuclear lamin-genome contacts. Genome Biol 2017; 18:21.
Swift J, Ivanovska IL, Buxboim A, et al. Nuclear Lamin-A scales with tissue stiffness and enhances matrix-directed differentiation. Science 2013; 341:1240104.
Earle AJ, Kirby TJ, Fedorchak GR, et al. Mutant lamins cause nuclear envelope rupture and DNA damage in skeletal muscle cells. Nat Mater 2020; 19:464–473.
Azibani F, Muchir A, Vignier N, et al. Striated muscle laminopathies. Semin Cell Dev Biol 2014; 29:107–115.
Maggi L, Quijano-Roy S, Bönnemann C, Bonne G. 253rd ENMC international workshop: striated muscle laminopathies - natural history and clinical trial readiness. 24-26 June 2022, Hoofddorp, the Netherlands. Neuromuscul Disord 2023; 33:498–510.
Bonne G, Mercuri E, Muchir A, et al. Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the Lamin A/C gene. Ann Neurol 2000; 48:170–180.
Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sudden death in patients with Lamin A/C gene mutations. N Engl J Med 2006; 354:209–210.
Wahbi K, Ben Yaou R, Gandjbakhch E, et al. Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies. Circulation 2019; 140:293–302.
Rootwelt-Norberg C, Christensen AH, Skjølsvik ET, et al. Timing of cardioverter-defibrillator implantation in patients with cardiac laminopathies—external validation of the LMNA-risk ventricular tachyarrhythmia calculator. Heart Rhythm 2023; 20:423–429.
Bennett JS, Gordon DM, Majumdar U, et al. Use of machine learning to classify high-risk variants of uncertain significance in lamin A/C cardiac disease. Heart Rhythm 2022; 19:676–685.
Gregory EF, Kalra S, Brock T, et al. Caenorhabditis elegans models for striated muscle disorders caused by missense variants of human LMNA. PLOS Genet 2023; 19:e1010895.
Storey EC, Holt I, Brown S, et al. Proteomic characterization of human LMNA-related congenital muscular dystrophy muscle cells. Neuromuscul Disord 2024; 38:26–41.
Elzamzami FD, Samal A, Arun AS, et al. Native lamin A/C proteomes and novel partners from heart and skeletal muscle in a mouse chronic inflammation model of human frailty. Front Cell Dev Biol 2023; 11:1240285.
Mathiesen SB, Lunde M, Aronsen JM, et al. The cardiac syndecan-4 interactome reveals a role for syndecan-4 in nuclear translocation of muscle LIM protein (MLP). J Biol Chem 2019; 294:8717–8731.
Luosujärvi H, Aro J, Tokola H, et al. A novel p38 MAPK target dyxin is rapidly induced by mechanical load in the heart. Blood Press 2010; 19:54–63.
Sakkinen H, Luosujarvi H, Karvonen T, et al. Transcriptional cofactor dyxin mediates hypertrophic response in the heart during angiotensin II-induced hypertension. J Physiol Pharmacol 2023; 74:623–632.
Luo G, Wang R, Zhou H, Liu X. ALDOA protects cardiomyocytes against H/R-induced apoptosis and oxidative stress by regulating the VEGF/Notch 1/Jagged 1 pathway. Mol Cell Biochem 2020; 476:775–783.
Tachibana S, Yu NK, Li R, et al. Perm1 protects the heart from pressure overload–induced dysfunction by promoting oxidative metabolism. Circulation 2023; 147:916–919.
Yamada S, Ko T, Ito M, et al. TEAD1 trapping by the Q353R-Lamin A/C causes dilated cardiomyopathy. Sci Adv 2023; 9:eade7047.
Lin KC, Park HW, Guan KL. Regulation of the Hippo pathway transcription factor TEAD. Trends Biochem Sci 2017; 42:862–872.
Liu R, Jagannathan R, Sun L, et al. Tead1 is essential for mitochondrial function in cardiomyocytes. Am J Physiol-Heart Circ Physiol 2020; 319:H89–99.
Owens DJ, Fischer M, Jabre S, et al. Lamin mutations cause increased YAP nuclear entry in muscle stem cells. Cells 2020; 9:E816.
Tsika RW, Ma L, Kehat I, et al. TEAD-1 overexpression in the mouse heart promotes an age-dependent heart dysfunction. J Biol Chem 2010; 285:13721–13735.
Ikegami K, Secchia S, Almakki O, et al. Phosphorylated Lamin A/C in the nuclear interior binds active enhancers associated with abnormal transcription in Progeria. Dev Cell 2020; 52:699–713. e11.
Gesson K, Rescheneder P, Skoruppa MP, et al. A-type lamins bind both hetero- and euchromatin, the latter being regulated by lamina-associated polypeptide 2 alpha. Genome Res 2016; 26:462–473.
Escudeiro-Lopes S, Filimonenko VV, Jarolimová L, Hozák P. Lamin A/C and PI(4,5)P2—a novel complex in the cell nucleus. Cells 2024; 13:399.
Philimonenko VV, Zhao J, Iben S, et al. Nuclear actin and myosin I are required for RNA polymerase I transcription. Nat Cell Biol 2004; 6:1165–1172.
Sobol M, Krausová A, Yildirim S, et al. Nuclear phosphatidylinositol 4,5-bisphosphate islets contribute to efficient RNA polymerase II-dependent transcription. J Cell Sci 2018; 131:jcs211094.
Robson MI, de las Heras JI, Czapiewski R, et al. Tissue-specific gene repositioning by muscle nuclear membrane proteins enhances repression of critical developmental genes during myogenesis. Mol Cell 2016; 62:834–847.
Ramirez-Martinez A, Zhang Y, Chen K, et al. The nuclear envelope protein Net39 is essential for muscle nuclear integrity and chromatin organization. Nat Commun 2021; 12:690.
Bertrand AT, Brull A, Azibani F, et al. Lamin A/C assembly defects in LMNA-congenital muscular dystrophy is responsible for the increased severity of the disease compared with Emery–Dreifuss muscular dystrophy. Cells 2020; 9:844.
Zhang Y, Ramirez-Martinez A, Chen K, et al. Net39 protects muscle nuclei from mechanical stress during the pathogenesis of Emery-Dreifuss muscular dystrophy. J Clin Invest 2023; 133:e163333.
Chai RJ, Werner H, Li PY, et al. Disrupting the LINC complex by AAV mediated gene transduction prevents progression of Lamin induced cardiomyopathy. Nat Commun 2021; 12:4722.
Tan CY, Chan PS, Tan H, et al. Systematic in vivo candidate evaluation uncovers therapeutic targets for LMNA dilated cardiomyopathy and risk of Lamin A toxicity. J Transl Med 2023; 21:690.
Leong EL, Khaing NT, Cadot B, et al. Nesprin-1 LINC complexes recruit microtubule cytoskeleton proteins and drive pathology in Lmna-mutant striated muscle. Hum Mol Genet 2023; 32:177–191.
Amiad Pavlov D, Unnikannan C, Lorber D, et al. The LINC complex inhibits excessive chromatin repression. Cells 2023; 12:932.
Shaw NM, Rios-Monterrosa JL, Fedorchak GR, et al. Effects of mutant lamins on nucleo-cytoskeletal coupling in Drosophila models of LMNA muscular dystrophy. Front Cell Dev Biol 2022; 10:934586.
Choi JC, Muchir A, Wu W, et al. Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by Lamin A/C gene mutation. Sci Transl Med 2012; 4:144ra102.
Ramos FJ, Chen SC, Garelick MG, et al. Rapamycin reverses elevated mTORC1 signaling in Lamin A/C–deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med 2012; 4:144ra103.
Wu W, Jin Q, Östlund C, et al. mTOR inhibition prolongs survival and has beneficial effects on heart function after onset of Lamin A/C gene mutation cardiomyopathy in mice. Circ Heart Fail 2024; 17:e011110.
Muchir A, Wu W, Choi JC, et al. Abnormal p38 mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A/C gene mutation. Hum Mol Genet 2012; 21:4325–4333.
MacRae CA, Taylor MRG, Mestroni L, et al. Efficacy and safety of ARRY-371797 in LMNA -related dilated cardiomyopathy: a Phase 2 study. Circ Genomic Precis Med 2023; 16:e003730.
Bannasch DL, Oertle DT, Vo J, et al. Naturally occurring canine laminopathy leading to a dilated and fibrosing cardiomyopathy in the Nova Scotia Duck Tolling Retriever. Sci Rep 2023; 13:19077.
Davies BSJ, Barnes RH, Tu Y, et al. An accumulation of nonfarnesylated prelamin A causes cardiomyopathy but not progeria. Hum Mol Genet 2010; 19:2682–2694.
Luo X, Jia H, Wang F, et al. Primate model carrying LMNA mutation develops dilated cardiomyopathy. JACC Basic Transl Sci 2024; 9:380–395.
Yang J, Argenziano MA, Burgos Angulo M, et al. Phenotypic variability in iPSC-induced cardiomyocytes and cardiac fibroblasts carrying diverse LMNA mutations. Front Physiol 2021; 12:778982.
Le Dour C, Chatzifrangkeskou M, Macquart C, et al. Actin-microtubule cytoskeletal interplay mediated by MRTF-A/SRF signaling promotes dilated cardiomyopathy caused by LMNA mutations. Nat Commun 2022; 13:7886.
Wallace M, Zahr H, Perati S, et al. Nuclear damage in LMNA mutant iPSC-derived cardiomyocytes is associated with impaired lamin localization to the nuclear envelope. Mol Biol Cell 2023; 34:mbcE21100527.
Fuoco C, Rizzi R, Biondo A, et al. In vivo generation of a mature and functional artificial skeletal muscle. EMBO Mol Med 2015; 7:411–422.
Afshar Bakooshli M, Lippmann ES, Mulcahy B, et al. A 3D culture model of innervated human skeletal muscle enables studies of the adult neuromuscular junction. eLife 2019; 8:e44530.
Andersen J, Revah O, Miura Y, et al. Generation of functional human 3D cortico-motor assembloids. Cell 2020; 183:1913–1929. e26.
Benarroch L, Madsen-Østerbye J, Abdelhalim M, et al. Cellular and genomic features of muscle differentiation from isogenic fibroblasts and myoblasts. Cells 2023; 12:1995.
Pinton L, Khedr M, Lionello VM, et al. 3D human induced pluripotent stem cell–derived bioengineered skeletal muscles for tissue, disease and therapy modeling. Nat Protoc 2023; 18:1337–1376.